Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Fibrolamellar Hepatocellular Carcinoma

Children's Oncology GroupSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

25 Active assets in the Fibrolamellar Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Children's Oncology Group
Phase 3BB
FLUOROURACILUM
M.D. Anderson Cancer Center
Phase 3BB
Nivolumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2B
Sorafenib
St. Jude Children's Research Hospital
Phase 3B
Inno-206
Children's Oncology Group
Phase 3B

View all 37 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →